Demant A/S (WILYY) Stock Price, News & Analysis

Company Overview

Demant A/S is a Denmark-based hearing healthcare company that develops, manufactures and distributes products and services designed to help people with hearing loss and other communication needs. The company serves consumers and hearing care professionals through activities spanning hearing aids, diagnostic equipment, hearing care services and specialized communications technology.

Its portfolio includes hearing aids and related software, audiological diagnostic instruments, and technologies used by hearing care professionals to assess and manage hearing conditions. Demant’s businesses operate under brands including Oticon, Bernafon, Sonic and Philips Hearing Solutions, which is offered through a licensing partnership. The company also provides hearing care through retail and clinic networks, including the Audika brand in a number of markets.

Founded in 1904 after Hans Demant obtained a hearing device for his wife, the company has developed into an international hearing healthcare group headquartered in Denmark. Demant serves customers through operations and distribution networks across Europe, North America, Asia-Pacific and other global markets. Its products and services are sold through hearing care professionals, clinics, retail locations and other specialized channels.

Demant is led by President and Chief Executive Officer Søren Nielsen. The company’s shares trade on Nasdaq Copenhagen, while its American depositary receipts trade over the counter in the United States under the symbol WILYY.

Key Stats

• Today's Range: $23.58 to $24.46
• 50-Day Range: $20.66 to $24.50
• 52-Week Range: $13.45 to $24.50
• Volume: 544 shs
• Average Volume: 416 shs
• Market Capitalization: $9.98 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Demant A/S Stock Analysis - MarketRank™

Demant A/S scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Buy

Consensus Rating

Demant A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Demant A/S has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.15%

Earnings Growth

Earnings for Demant A/S are expected to grow by 12.15% in the coming year, from $1.07 to $1.20 per share.

Price to Book Value per Share Ratio

Demant A/S has a P/B Ratio of 6.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Demant A/S has been sold short.

Short Interest Ratio / Days to Cover

Demant A/S has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Demant A/S has recently decreased by 96.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Demant A/S does not currently pay a dividend.

Dividend Growth

Demant A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.80

News Sentiment

Demant A/S has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Demant A/S this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Demant A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Demant A/S has minimal institutional ownership at this time.

Company Calendar

• Today: 10/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:WILYY
• Previous Symbol: NASDAQ:WILYY
• CIK: N/A
• Web: www.demant.com
• Phone: (453) 917-7300
• Fax: 45-3927-8900
• Employees: 26,704
• Year Founded: 1904

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.48 billion
• Price / Sales: 2.87
• Cash Flow: $0.88 per share
• Price / Cash Flow: 26.82
• Book Value: $3.51 per share
• Price / Book: 6.72

Miscellaneous

• Outstanding Shares: 423,510,000
• Free Float: N/A
• Market Cap: $9.98 billion
• Optionable: Not Optionable
• Beta: 1.16